Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.

More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.

Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...

Insmed will no longer develop Brinsupri for the treatment of HS. Credit: ako photography / Shutterstock.com. Insmed is putting a stop to the development of Brinsupri (brensocatib) in hidradenitis ...

Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection.

Genentech's divarasib posts this win as KRAS-targeting therapies demonstrate ‘game-changing’ potential in hard-to-treat cancers.

Natera and Aveta Biomics have entered into a strategic partnership to support the latter’s AVTA 30-01, a global Phase III head and neck cancer trial assessing APG-157 in patients with LA-HNSCC.

NeuroSense now has FDA clearance to take PrimeC to Phase III in ALS, as competition in the indication intensifies.

Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved its primary safety endpoint.

AstraZeneca has signed a strategic collaboration agreement with Abbisko Therapeutics to study the combined use of Tagrisso and lumipodlin in patients with NSCLC.

Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial, assessing the oral small molecule inhibitor emavusertib along with zanubrutinib for patients with CLL.

Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead candidate OLN324 for the treatment of DME and wAMD.